AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Johnson & Johnson
XNYS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S5SHQ9
263.81▼ 3.80 (-1.42%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
267.61
Day's Range
262.40 – 266.03
52-Week Range
184.66 – 281.07
Volume
5.3M
Avg Volume
7.2M
Share Statistics
Shares Outstanding
Employees
140.8K
Exchange
XNYS
Listed
1944-09-25
Share count as of October 15, 2026

Johnson & Johnson (JNJ) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Johnson & Johnson (JNJ)
What is Johnson & Johnson's Market Cap?
Johnson & Johnson's Market Cap is $635.1B, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's Enterprise Value?
Johnson & Johnson's Enterprise Value is $662.5B, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's Trailing P/E?
Johnson & Johnson's Trailing P/E is 39.5×, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's Price / Sales?
Johnson & Johnson's Price / Sales is 6.4×, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's EV / Revenue?
Johnson & Johnson's EV / Revenue is 6.7×, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's EV / EBITDA?
Johnson & Johnson's EV / EBITDA is 24.7×, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's Revenue (TTM)?
Johnson & Johnson's Revenue (TTM) is $99.3B, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's Net Income (TTM)?
Johnson & Johnson's Net Income (TTM) is $16.1B, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's EBITDA?
Johnson & Johnson's EBITDA is $26.8B, based on as-reported figures from SEC (XBRL) filings.
What is Johnson & Johnson's Diluted EPS (TTM)?
Johnson & Johnson's Diluted EPS (TTM) is 6.69, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · JNJAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemSep 27, 2026Jun 28, 2026Mar 29, 2026Dec 28, 2025Sep 28, 2025Jun 29, 2025Mar 30, 2025Dec 29, 2024Sep 29, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Oct 1, 2023Jul 2, 2023Apr 2, 2023Jan 1, 2023Oct 2, 2022
Sales to customers (Note 9)
YoY growth+5.9%+6.6%+9.9%+9.1%+6.8%
Sales to customers percent to sales—
Cost of products sold
Cost of products sold percent to sales—
Gross profit
% of revenue68.1%68.2%66.3%67.6%69.6%
Gross Profit Percent To Sales—
Selling, marketing and administrative expenses
Selling marketing and administrative expenses percent to sales—
Research and development expense
Research and development expense percent to sales—
In-process research and development impairments
In-process research and development percent to sales—
Interest income
Interest income percent to sales—
Interest expense, net of portion capitalized
Interest expense, net of portion capitalized percent to sales—
Other (income) expense, net
Other (income) expense, net percent to sales—
Restructuring (Note 12)
Restructuring charge percent to sales—
Earnings before provision for taxes on income
Earnings before provision for taxes on income percent to sales—
(Benefit from)/Provision for taxes on income (Note 5)
Provision for taxes on income percent to sales—
Net earnings from continuing operations percent of sales—
Net earnings
% of revenue0.8%21.9%21.8%20.8%21.5%
NET EARNINGS PER SHARE
Total net earnings per share - basic (in dollars per share)
Total net earnings per share - diluted (in dollars per share)